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W
hether he’s chasing down a 
novel disease gene or making 
rebounds on the basketball 
court, Qing Zhong loves a spirited compe-
tition. He was trained as a physician in 
China, but soon found that his real passion 
was in biological research. He decided 
that his best chance for success in his new 
profession would come from working in a 
major laboratory in the United States. He 
came to San Antonio, Texas to do his grad-
uate work with Wen-Hwa Lee, studying 
the genetic basis of breast cancer (1–3). 
He next pursued his postdoctoral studies 
on apoptosis in Xia-
odong Wang’s laborato-
ry. While there, he 
scored big by using 
classical biochemistry 
methods of gene dis-
covery to uncover an 
involvement of the 
MULE protein (an E3 
ubiquitin ligase) in 
apoptosis (4, 5).
Zhong is now head-
ing up his own labora-
tory at Berkeley, where 
he uses the methods he 
learned in his postdoc 
to identify new players 
in autophagy, a critical 
pathway for cellular homeostasis. Zhong 
calls the autophagy pathway “the next 
apoptosis”, because he believes that, like 
apoptosis, it will turn out to be central to 
human health and disease. He took a 
“time-out” to talk to us about his work, 
before heading out to the basketball court 
to teach the undergrads a thing or two.
PLAYING TO WIN
What kind of approach do you bring to 
your work?
I like thinking of myself as a competitor. In 
science and in sports, I play very hard, and 
I bring a lot of energy to my work—but 
while I respect a hard worker, I respect a 
smart one even more. And I like to win. So 
I play hard and I play smart, but I play fair.
So you’re an athlete.
I like any kind of games, but especially 
basketball. I still play with undergrads 
here at Berkeley. I don’t play one-on-one 
with them anymore, but I can be a very 
good ball player. That’s why I put more 
attention into defense rather than offense 
right now. These kids can really score, 
but I help them to get rebounds and 
blocks. I like to make them think, to 
coach them to success on the court and in 
the laboratory.
Are you a fan of professional sports too?
I’m a huge fan of Yao Ming and the Hou-
ston Rockets. Yao Ming is defi  nitely my 
hero. I enjoy watching him play a lot—I 
have an NBA pass to watch every game of 
his. He loves to play center, and that’s not 
an easy job, but he’s fearless. I play cent-
er, so I know what it’s like: people will 
bump you, hit you, and push you. But he 
can stay calm, and still play tough. That’s 
something I think I admire the most about 
his style. It’s an attribute that I personally 
want to have.
Did you ever want to be a professional 
basketball player?
No. In fact, as a child, I wanted to be a 
physician. I grew up in Beijing, China, in 
a family where a lot of my relatives were 
working in medicine. My grandfather is 
a physician, and he has six brothers and 
two sisters—and half of them are in-
volved in medicine. Some of them are 
surgeons, some are in obstetrics and 
gynecology, and others are practitioners 
of Chinese traditional medicine. They 
even have their own clinic, and have all 
worked at major hospitals in China. So 
with a background like that, it’s no won-
der I wanted to be a doctor when I went 
to college.
Did something happen in college to 
change your mind?
I went to Peking Union Medical College. 
It’s famous because it’s one of the two 
medical schools in China that were 
founded by the Rockefeller Foundation, 
about 100 years ago. It’s also famous for 
having a tough medical program. Most 
medical schools in China have fi  ve- or 
six-year programs, but this one has an 
eight-year program.
I have to say I wasn’t really a great 
medical student, but I found a new pas-
sion at the end of my program, when we 
had to do eight months of research train-
ing. I joined a laboratory studying sper-
matogenesis and I worked really hard—
day and night. I didn’t make any scientifi  c 
breakthroughs as a newcomer, but my 
professors were very nice and supportive, 
which really encouraged me.
Did you know you were going to do 
research from then on?
Actually, I fi  rst did a one-year residency 
in the cancer hospital of the Chinese 
Academy of Medical Science. But this 
only confi  rmed that I wanted to be a sci-
entist rather than a doctor. We saw lots of 
patients, but there was very little discus-
sion about why a certain drug functioned 
a certain way. I was curious about things 
beyond my daily work as a doctor, such as 
fi  nding new treatments, and understand-
ing the mechanisms behind cancer and 
the drugs used to treat it. That’s why I de-
cided to work in research.
Qing Zhong
Qing Zhong uses a classical cell-free biochemistry approach to identify 
genes involved in autophagy, and to uncover their links to human disease.
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EYE ON THE BALL
Which laboratory did you choose for 
your graduate studies?
I joined Dr. Wen-Hwa Lee’s laboratory at 
the University of Texas Health Center to 
study for my PhD. He’s one of the three 
scientists who fi  rst cloned Retinoblastoma, 
a tumor suppressor gene that’s mutated in 
a lot of cancers. In Wen-Hwa’s laboratory 
I worked on Breast Cancer Gene 1 
(BRCA1), which is mutated in more than 
half of all familial breast and ovarian can-
cers. We found that BRCA1 works to-
gether with the Rad50/Mre11/Nbs1 pro-
tein complex in DNA repair.
What made you switch from breast 
cancer to apoptosis for your 
postdoctoral work?
After working on BRCA1 for some time, I 
decided that instead of just studying one 
gene, I wanted to master a whole pathway, 
to ask, “What’s the critical step? What are 
the important genes involved in this path-
way?” I wanted to have the tools neces-
sary for discovering novel genes, or novel 
pathways, so we could fi  gure out how they 
contribute to human disease. So when I 
applied to laboratories to do a postdoc, I 
was specifi  cally looking for one with a 
strong expertise in biochemistry.
And that’s why you selected 
Dr. Xiaodong Wang’s laboratory.
Yes. Xiaodong is famous for his biochem-
ical approach to mapping out the apop-
totic pathway. People basically use two 
approaches to map out novel genes and 
pathways. One is genetics, and the other 
is biochemistry. Ten years ago, the human 
and mouse genome had not been se-
quenced and mammalian genetic screens 
were not so easy. If you wanted to do a 
genetic screen, you would generally use 
yeast or fl  ies. But, because of my medical 
background, I’ve always wanted to study 
disease processes in mammalian systems. 
The biochemical 
system that Xiao-
dong’s laboratory 
used allowed me to 
do that.
Xiaodong used a 
very classical bio-
chemical approach: 
a cell-free fractionation system. With this 
approach, which I still use in my labora-
tory today, you start from the activity you 
are interested in and work down to iden-
tifying the protein responsible for that 
activity. In Xioadong’s laboratory we 
identifi  ed a new E3 ubiquitin ligase for 
the Bcl2 family member Mcl1. We called 
this new protein MULE, and ended up 
cloning the gene that encodes it. It’s actu-
ally the fi  rst ubiquitin ligase to be identi-
fi  ed by this method.
GAME PLAN
And you are continuing to use this 
approach in your new laboratory?
Yes, but now we are looking at autophagy. 
The autophagy lysosome pathway was 
fi  rst characterized almost 50 years ago, 
but until recently everyone thought it was 
a constitutively active housekeeping 
pathway, so it didn’t draw much atten-
tion. But now people are realizing that 
autophagy is a highly regulated process. 
It responds to stress, it’s important for 
normal development, and it’s also in-
volved in a lot of human diseases, such as 
cancers, autoimmune diseases, and path-
ogen biology.
I think the autophagy fi   eld now is 
where the apoptosis fi  eld was ten years 
ago. We don’t yet know very much about 
the biochemistry of this pathway, so there 
is a lot of room to make important new 
discoveries. The key questions that I want 
to attack are: how is autophagy induced, 
and where does its specifi  city come from? 
Autophagy can degrade many different 
targets, from bacterial pathogens to or-
ganelles to aggregated proteins—so how 
are these things specifi  cally targeted for 
degradation? How does the cell decide 
what things to degrade, and what to leave 
alone? Is there some key event regulating 
this pathway? It’s very exciting to be 
working on these kinds of questions.
What inspires you in 
your work right now?
I just love thinking about 
questions like: why do 
we have cancer? I know 
that we won’t have an-
swers for that question 
in my lifetime, but I love 
thinking about it because 
it is so complex. It’s 
such a puzzle.
When I was in Xia-
odong’s laboratory, I 
used to joke with my 
lab-mates about want-
ing to win the next No-
bel Prize [laughs]. But 
it’s not really about 
winning a prize. I’m 
just always thinking 
about the next big ques-
tion. I’d like to know what’s the key step 
in autophagy. If we can fi  nd out what that 
is, can we target it with a drug? Can we 
use the drug to treat a human disease? I 
would love if I could be involved in some-
thing like that.
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“I used to joke 
with my lab-
mates about 
wanting to 
win the next 
Nobel Prize 
[laughs]. But 
it’s not really 
about winning 
a prize. I’m 
just always 
thinking about 
the next big 
question.”
Zhong sports the team jersey of his basketball 
idol, Yao Ming, who exhibits the kind of 
sporting competitiveness that Zhong admires.
Autophagosomes (punctate staining) form after rapamycin treatment.